We are live on
!
Find out more
William Blair & Company Portfolio holdings
AUM
$34.9B
1-Year Est. Return
18.88%
This Fund
S&P 500
This Quarter
Est. Return
+5.64%
1 Year Est. Return
+18.88%
3 Year Est. Return
+73.84%
5 Year Est. Return
+90.13%
10 Year Est. Return
+512.03%
AUM
$11.3B
AUM Growth
+$589M
(+5.5%)
Cap. Flow
+$20.5M
Cap. Flow
% of AUM
0.18%
Top 10 Holdings %
Top 10 Hldgs %
17.02%
Holding
1,387
New
148
Increased
486
Reduced
533
Closed
92
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fortive
FTV
|
+$47.4M |
| 2 |
AGN
Allergan plc
AGN
|
+$38.9M |
| 3 |
NVRO
NEVRO CORP.
NVRO
|
+$24.1M |
| 4 |
Netflix
NFLX
|
+$21.5M |
| 5 |
Waste Management
WM
|
+$21.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$45.3M |
| 2 |
MDVN
MEDIVATION, INC.
MDVN
|
+$33.2M |
| 3 |
Danaher
DHR
|
+$28.3M |
| 4 |
FLTX
Fleetmatics Group PLC
FLTX
|
+$25.2M |
| 5 |
Healthcare Services Group
HCSG
|
+$24.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.99% |
| 2 | Technology | 15.43% |
| 3 | Financials | 11.87% |
| 4 | Industrials | 11.27% |
| 5 | Consumer Discretionary | 10.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Intuit
INTU
$86.5B
| $29.1M | 0.26% |
264,755
+2,129
| +0.8% | +$238K |
|
102
Chevron
CVX
$392B
| $28.4M | 0.25% |
276,200
-17,215
| -6% | -$1.76M |
|
103
Amgen
AMGN
$208B
| $28M | 0.25% |
168,034
+2,287
| +1% | +$387K |
|
|
NVRO
104
DELISTED
NEVRO CORP.
NVRO
| $27.9M | 0.25% |
+266,867
| New | +$24.1M |
|
105
Vanguard High Dividend Yield ETF
VYM
$80.9B
| $27.1M | 0.24% |
376,244
+15,676
| +4% | +$1.14M |
|
106
Wells Fargo
WFC
$261B
| $27.1M | 0.24% |
612,728
-121,679
| -17% | -$5.82M |
|
107
3M
MMM
$90.9B
| $27.1M | 0.24% |
183,657
+5,068
| +3% | +$757K |
|
108
ScottsMiracle-Gro
SMG
$3.82B
| $27.1M | 0.24% |
324,866
+17,398
| +6% | +$1.37M |
|
109
JB Hunt Transport Services
JBHT
$25.5B
| $26M | 0.23% |
320,714
-4,536
| -1% | -$370K |
|
110
McDonald's
MCD
$192B
| $25.5M | 0.23% |
221,407
+339
| +0.2% | +$40.2K |
|
111
Blackrock
BLK
$169B
| $25.4M | 0.22% |
69,940
+2,357
| +3% | +$858K |
|
|
MMP
112
DELISTED
Magellan Midstream Partners, L.P.
MMP
| $24.9M | 0.22% |
351,828
-479
| -0.1% | -$34.2K |
|
113
Aon
AON
$76.5B
| $24.4M | 0.22% |
216,716
+47,013
| +28% | +$5.18M |
|
|
114
Netflix
NFLX
$299B
| $24.1M | 0.21% |
2,448,450
+2,249,790
| +1,132% | +$21.5M |
|
115
Pfizer
PFE
$143B
| $24M | 0.21% |
748,357
+3,580
| +0.5% | +$120K |
|
|
PGND
116
DELISTED
PRESS GANEY HOLDINGS INC COM STK (DE)
PGND
| $24M | 0.21% |
594,530
-533,289
| -47% | -$21.5M |
|
117
CVS Health
CVS
$133B
| $23.9M | 0.21% |
268,466
+1,037
| +0.4% | +$97.9K |
|
118
Vanguard Real Estate ETF
VNQ
$39.2B
| $23.8M | 0.21% |
274,563
+24,927
| +10% | +$2.22M |
|
119
Qualcomm
QCOM
$155B
| $23.5M | 0.21% |
343,603
-5,769
| -2% | -$351K |
|
120
VF Corp
VFC
$5.63B
| $23.5M | 0.21% |
445,713
-78,927
| -15% | -$4.56M |
|
121
Omnicom Group
OMC
$21.6B
| $23.4M | 0.21% |
275,335
+1,555
| +0.6% | +$130K |
|
122
Ametek
AME
$55.4B
| $23.4M | 0.21% |
488,742
-49,530
| -9% | -$2.36M |
|
123
Intel
INTC
$455B
| $23.2M | 0.21% |
614,296
+154,425
| +34% | +$5.47M |
|
|
COL
124
DELISTED
Rockwell Collins
COL
| $23.2M | 0.2% |
274,869
-16,024
| -6% | -$1.35M |
|
|
125
Waste Management
WM
$90.6B
| $23.1M | 0.2% |
361,993
+326,400
| +917% | +$21.3M |
|
Similar funds
SAM
VIA
William Blair & Company's Q3 2016 Portfolio in Review
As of Q3 2016, William Blair & Company held 1,387 positions worth $11.3B, up 5.5% from $10.7B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
William Blair & Company's Q3 2016 filing shows 148 new, 486 increased, 533 reduced and 92 closed positions. Its largest new stake was Fortive: 1,476,720 shares worth $47.4M. The largest sale was Gilead Sciences, an estimated $45.3M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 20% a quarter earlier, followed by Technology and Financials.
- William Blair & Company's largest Q3 2016 buy was Fortive: 1,476,720 shares worth $47.4M.
- William Blair & Company added most to Allergan plc in Q3 2016, an estimated $38.9M increase.
- William Blair & Company's biggest Q3 2016 reduction was Gilead Sciences, cutting an estimated $45.3M.
- William Blair & Company fully exited IHS INC CL-A COM STK in Q3 2016, selling an estimated $6.24M.
- William Blair & Company's ten largest holdings make up 17% of its $11.3B portfolio in Q3 2016.
- William Blair & Company opened 148 new positions and closed 92 in Q3 2016.
- William Blair & Company's portfolio value rose 5.5% quarter-over-quarter to $11.3B.
Based on William Blair & Company's 13F filing for Q3 2016, filed 14 Nov 2016.